Simon Berg & Andreas Klow Skip to content Explore When autocomplete results are available use up and down arrows to review and enter to select
Hampl SE, Hassink SG, Skinner AC, et al
Insurance may cover some costs, but many patients pay cash prices
This was a single-dose study at the lowest therapeutic dose (5 mg), and there are still no data on the effects of tirzepatide on breastfed infants or on milk production
Recent trials have shown: Up to 20% body weight reduction with weekly GLP-1 agonists (Wilding et al., NEJM) Improvements in HbA1c, fasting glucose, and cardiovascular outcomes (Marso et al., NEJM) This drug class is now widely used for: Obesity (with or without diabetes) Type 2 diabetes PCOS-related insulin resistance Metabolic syndrome Common Side Effects and Patient Concerns Despite their benefits, GLP-1 agonists are not without risks or drawbacks
Here is the fundamental math